Ifoside M 200 Injection contains Ifosfamide 2 gm and Mesna 200 mg, a combination formulation widely used in oncology practice as part of established chemotherapy regimens. Ifosfamide serves as the primary anticancer agent, while Mesna helps protect the urinary tract from specific toxic metabolites generated during Ifosfamide therapy. The combination is designed to provide effective cancer treatment while enhancing patient safety during chemotherapy administration.

Ifosfamide belongs to the class of alkylating antineoplastic agents and works by damaging the DNA of rapidly dividing cancer cells, thereby preventing their growth and multiplication. This action ultimately leads to cancer cell death and helps control tumor progression. Mesna acts as a uroprotective agent by binding harmful metabolites in the urinary tract, helping reduce the risk of hemorrhagic cystitis and other bladder-related complications associated with Ifosfamide treatment.

The injection is commonly utilized in the treatment of sarcomas, testicular cancer, lymphomas, ovarian cancer, lung cancer, and several other malignancies as determined by an oncology specialist. It is often administered in combination with other chemotherapy medicines to achieve improved therapeutic outcomes. Careful patient monitoring throughout therapy helps ensure treatment effectiveness while minimizing potential adverse effects.

With the growing need for advanced oncology therapies and comprehensive chemotherapy solutions, Ifoside M 200 Injection maintains strong demand in the anticancer segment. Its established role in cancer treatment protocols, broad clinical acceptance, and importance in supportive chemotherapy care make it a valuable product for retailers and distributors. The product offers significant business potential and sustainable growth opportunities within the expanding oncology pharmaceutical market.

Ifoside M 200 Injection may cause nausea, vomiting, fatigue, weakness, loss of appetite, hair loss, diarrhea, low blood cell counts, and injection site reactions. Bone marrow suppression, infections, kidney function abnormalities, urinary tract irritation, neurological symptoms, bleeding tendencies, and electrolyte imbalances may occur and require close medical supervision.

Ifoside M 200 Injection is indicated for the treatment of sarcomas, testicular cancer, lymphomas, ovarian cancer, lung cancer, and other malignancies as determined by an oncology specialist. It helps control cancer cell growth while supporting safer administration of Ifosfamide-containing chemotherapy regimens.

This medication should be administered only by qualified healthcare professionals experienced in cancer chemotherapy. Regular monitoring of blood counts, kidney function, liver function, hydration status, and overall patient condition is essential throughout treatment. Patients should immediately report fever, unusual bleeding, urinary symptoms, confusion, severe fatigue, or signs of infection. Treatment should always be individualized according to the patient's condition and clinical response.

Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep the vial in its original packaging until use and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of deterioration.